Literature DB >> 11445064

Dyslipidemia.

Adam M. Cohen1, Daniel J. Rader.   

Abstract

The major goal in treatment of patients with dyslipidemia is to decrease the short- and long-term incidence of cardiovascular events, including myocardial infarction, unstable angina, stroke, and death. A second goal in patients with severe hypertriglyceridemia is to decrease the risk of acute pancreatitis. Improvement of the lipid profile can be achieved through a combination of aggressive lifestyle modification and effective drug therapy. Treatment should be tailored to the individual patient, based on the specific lipid abnormalities, the presence or absence of pre-existing coronary artery or other atherosclerotic vascular disease, and an assessment of overall cardiovascular risk.

Entities:  

Year:  2001        PMID: 11445064     DOI: 10.1007/s11936-001-0096-4

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  36 in total

Review 1.  Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.

Authors:  M Bottorff; P Hansten
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

2.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 3.  Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins.

Authors:  T A Pearson
Journal:  Am J Cardiol       Date:  1998-11-19       Impact factor: 2.778

4.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

5.  Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.

Authors:  A Cobos; A J Jovell; A García-Altés; R García-Closas; L Serra-Majem
Journal:  Clin Ther       Date:  1999-11       Impact factor: 3.393

6.  Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.

Authors:  S N Blair; D M Capuzzi; S O Gottlieb; T Nguyen; J M Morgan; N B Cater
Journal:  Am J Cardiol       Date:  2000-07-01       Impact factor: 2.778

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

9.  Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population.

Authors:  T A Miettinen; P Puska; H Gylling; H Vanhanen; E Vartiainen
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.